Pfizer Reports Third-Quarter 2010 Revenues of $16.2 Billion
- Details
- Category: Pfizer
Pfizer Inc. (NYSE: PFE) reported financial results for third-quarter 2010. Since the acquisition of Wyeth was completed on October 15, 2009, legacy Wyeth products and operations are reflected in the first three quarters of 2010, but not reflected in the first three quarters of 2009.
Simcere and Bristol-Myers Squibb Enter Innovative Partnership to Develop Early-Stage Oncology Compound
- Details
- Category: Bristol-Myers Squibb
Bristol-Myers Squibb Company (NYSE: BMY) and Simcere Pharmaceutical Group (NYSE: SCR), a leading pharmaceutical company in China, today announced an innovative strategic partnership to co-develop BMS-817378, a preclinical small molecule MET/VEGFR-2 inhibitor.
Lundbeck expects to deliver solid profits during a period of new product launches and patent expiries
- Details
- Category: Lundbeck
H. Lundbeck A/S (Lundbeck) today announces the financial floor guidance for the company. The guidance addresses a period of transition for Lundbeck, but also a period where we will maintain our strong financial position.
Phase III ROCKET AF Study of Rivaroxaban meets its primary efficacy endpoint with Comparable Safety vs. Warfarin
- Details
- Category: Bayer
Bayer announced the preliminary results of the pivotal Phase III ROCKET AF study of rivaroxaban, the full details of which will be presented at the Late Breaker Session on November 15, 2010, at the Scientific Sessions of the American Heart Association (AHA) in Chicago, USA.
Nycomed to accelerate expansion in China
- Details
- Category: Nycomed
Nycomed announced that it is significantly expanding its presence in China through the acquisition of a majority stake in Guangdong Techpool Bio-Pharma Co., Ltd. (Techpool), a fast-growing Chinese bio-pharmaceutical company based in Guangdong.
Novartis drug Afinitor® approved by FDA
- Details
- Category: Novartis
Novartis announced, that the US Food and Drug Administration (FDA) has approved Afinitor® (everolimus) tablets for patients with subependymal giant cell astrocytoma (SEGA), a benign brain tumor associated with tuberous sclerosis (TS), who require therapeutic intervention but are not candidates for curative surgical resection[2].
GlaxoSmithKline receives approval in Japan for two medicines: Revolade and Xyzal
- Details
- Category: GlaxoSmithKline
GlaxoSmithKline (GSK) announced that it has received approval in Japan from the Ministry of Health, Labour and Welfare for Revolade (eltrombopag) for the treatment of the blood disorder, chronic idiopathic thrombocytopenic purpura (ITP), and for Xyzal (levocetirizine dihydrochloride), the first new anti-histamine to be made available in Japan for eight years.
More Pharma News ...
- Sanofi-aventis to Acquire BMP Sunstone creating a Strong Consumer Healthcare Platform in China
- Merck KGaA Sells Théramex To Teva for EUR 265 million
- Bayer lifts sales and earnings again
- Patients With ALK-Positive Advanced Non-Small Cell Lung Cancer Responded to Crizotinib (PF-02341066)
- Bristol-Myers Squibb Third Quarter Featured Solid Operating Performance
- Merck KGaA Profit After Tax Jumps 45% to EUR 215 Million
- AstraZeneca initiates phase IIB study for AZD9773